GraMedica

GraMedica is a medical device manufacturer specializing in innovative foot and ankle surgical solutions. The company's flagship product is HyProCure, a minimally invasive sinus tarsi implant designed to realign the foot and correct biomechanical dysfunction. HyProCure is performed in less than 30 minutes with immediate weight-bearing capability and full activity resumption within two weeks. The device has demonstrated a 99% implant success rate in an 8-year peer-reviewed study published in Orthopaedic Surgery (2025), with over 100,000 implants placed globally since 2004. HyProCure maintains a complaint rate of 0.1% and removal rate of 5.2%, substantially lower than competing foot implants. GraMedica also offers HyProCure II (second-generation implant), Osteo-WEDGE (open wedge bone locking system for osteotomy), and Opti-Toe (lesser toe reconstruction device). The company supports surgeons with clinical training, patient education resources, and physician endorsement programs. Products are backed by 100+ clinical studies, including 25 peer-reviewed publications. GraMedica actively recruits medical device distributors and maintains a global presence across multiple countries and languages.